Another Study From ImClone Shows Mixed Results for Erbitux
ORLANDO, Fla. -- ImClone Systems (IMCL) released results Sunday from a late-stage clinical trial for its experimental cancer drug, Erbitux, that showed some positive trends, but that nonetheless, failed to meet the study's predefined clinical goal.
The data from the phase III study of 123 patients with advanced head and neck cancer were a mixed bag. The good news: Patients responded to Erbitux. The bad news: The study was too small to show a statistically significant benefit. These results are considered the most important test of Erbitux discussed so far because the clinical trial is randomized and controlled, or more scientifically rigorous than previous Erbitux studies. This clinical trial was also conducted by an outside, independent group -- the Eastern Cooperative Oncology Group. These results come just one day after ImClone released disappointing results from an earlier clinical trial of head and neck cancer patients. In the study detailed Sunday, half of the 123 head-and-neck cancer patients were given Erbitux and the standard chemo drug cisplatin. The other half were just given cisplatin. The trial's investigators hoped to show that patients in the Erbitux arm would show a doubling in progression-free survival to four months, compared with just two months in the control arm. That means patients taking Erbitux would go twice as long before their cancer got worse. When the data were analyzed, however, investigators found "no meaningful differences between the two group in terms of progression-free survival or overall survival," according to a press release issued by ImClone at the ASCO conference.TheStreet Premium Services For Personal Service: 877-471-2967
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 12,765.55 | 1,339.24 | 2,903.43 | 19.88 |
Oil *
117.27
|
|
DOWN
124.91 |
DOWN
12.71 |
DOWN
23.80 |
DOWN
0.59 |
10 Yr
1.99%
SPDR Gold
166.85
|
|
-0.97%
|
-0.94%
|
-0.81%
|
-2.88%
|
Data delayed 20 minutes |

Connect with TheStreet